BioLight Life Sciences Ltd. engages in investing in companies and managing projects in the field of eye diseases and ocular treatments. Its portfolio companies are IOptima Novel Glaucoma Treatment and Micromedic Technologies Ltd. The firm provides each of the subsidiaries with ongoing support, resources and expertise in science, regulation, business development, and intellectual property. IOptima Novel Glaucoma Treatment is engaged in the development, manufacturing and distribution of novel surgical treatments for glaucoma. Micromedic Technologies Ltd focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities.
BLLSF stock price ended at $0 on 日曜日, after dropping NaN%
On the latest trading day Feb 08, 2026, the stock price of BLLSF fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for BLLSF decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.